T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR
Plain-language summary
This trial is testing Allogenic stem cell transplant (ASCT) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years to 70 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Allogenic stem cell transplant (ASCT) (PROCEDURE): ASCT involves the infusion of stem cells collected from a donor (genetically similar, but not identical). | Salvage Therapy (PROCEDURE): This term encompasses a range of potential alternative regimens instead of allogeneic hematopoietic stem cell transplantation
Allogenic stem cell transplant (ASCT), Salvage Therapy
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details